Life sciences incubator PureTech Health (LON:PRTC), unfazed by the worldwide impact of the U.K.’s vote to leave the European Union, announced its latest venture today: Sonde Health, which aims to use a voice-based technology to diagnose mental and physical ailments. Based on technology licensed from the Mass. Institute of Technology’s Lincoln Laboratory, Sonde’s device is designed to analyze short vocal […]
PureTech Health said today it launched Alivio Therapeutics, a new novel tech business aiming to treat inflammatory disorders. The newly-launched company’s technology is based on hydrogel material designed to adhere to and deliver drugs to inflamed tissue based on the degree of inflammation, the Boston-based company said. The technology was jointly developed by Alivio co-founders […]
Stryker (NYSE:SYK) said yesterday that it’s eliminating the role of international president held by Ramesh Subrahmanian as it reorganizes its overseas business. After Subrahmanian’s departure, effective Dec. 31, he’s slated to stay on until March 31, 2016, as an advisor, Stryker said in a regulatory filing. International sales were down across the board during Stryker’s […]
(Reuters) — Boston-based PureTech Health kicked off its London listing on Friday, raising $171 million to fund further product development in the latest life sciences float in Britain. The U.S. health technology firm, which has on its board Pearson’s former chief executive Marjorie Scardino and former Sanofi chief executive Chris Viehbacher, said its listing valued […]
The Sync Project said it’s partnered with Berklee College of Music’s Institute for Creative Entrepreneurship as it explores the therapeutic effects of music.
(Reuters) — Boston-based PureTech Health plans to raise $160 million in a London listing, filling its coffers to fund product development and delivering a vote of confidence on the British life sciences sector.
The move by the U.S. health technology firm follows a similar decision by California-based drug discovery group Verseon to raise $100 million in London earlier this month.
April 17, 2015 by Scott Wooldridge
Tal Medical said today that it landed a $14 million Series B round it plans to use in backing clinical trials for its low-field magnetic stimulation technology as a non-invasive neurostimulation treatment for depression and bipolar disorder.